The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models

Resistance to microtubule targeting agents (MTA) represents a major drawback in successful cancer therapy with MTAs. Here we investigated the combined treatment modality of the novel MTA BAL101553 in combination with radiotherapy in paclitaxel and epothilone-resistant tumor models.

http://ift.tt/2uk0Srm